Equities research analysts at StockNews.com initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) in a report issued on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Price Performance
AEZS stock opened at $4.13 on Friday. Aeterna Zentaris has a 1-year low of $3.96 and a 1-year high of $12.00. The business has a 50 day simple moving average of $5.14 and a two-hundred day simple moving average of $6.67. The company has a market capitalization of $7.41 million, a price-to-earnings ratio of -0.28 and a beta of 1.55.
About Aeterna Zentaris
Further Reading
- Five stocks we like better than Aeterna Zentaris
- Options Trading – Understanding Strike Price
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Russell 2000 Index, How Investors Use it For Profitable Trading
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.